Latest Content

A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.

Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.

AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.

In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Living with stage IV kidney cancer for 10 years, one survivor shares how he manages scanxiety, uncertainty and the waiting between scans.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.

Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.

Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.

See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.